AstraZeneca has announced it will invest $50bn (£37bn) in the US by 2030, the latest in a string of pledges by pharmaceutical companies as the threat of Donald Trump’s tariffs looms over the industry.
The British drugmaker, which is headquartered in Cambridge, said its investment would fund a new drug manufacturing facility in Virginia and expand its research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas.
